Regen BioPharma Inc (RGBP)

[Carter]

"As we grow our CAR T-cell and other immunotherapy programs, we need the expertise of senior scientists associated with the top academic medical centers in the U.S. In fact, CAR T-cell therapy was first developed at the University of Pennsylvania and, with their big pharma partner Novartis, they got the first CAR T-cell therapy approval in 20171," said Dr. David Koos, CEO and Chairman. "We are absolutely delighted to have Drs. Reddy and Haris join us."